Journal Article
. 2017 Mar; 19(10):1134-1143.
doi: 10.1038/gim.2017.19.

21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013

Julie A Lynch 1 Brygida Berse 1 Nicole Coomer 2 John Kautter 1 
  • PMID: 28333918
  •     25 References
  •     3 citations


Purpose: We evaluated national patient-level utilization of the 21-gene recurrence score (21-gene RS) test among Medicare beneficiaries with breast cancer. We analyzed clinical, demographic, and regional factors that predict testing.

Methods: Using 2010-2013 Medicare claims, we conducted a retrospective study of breast cancer patients. The outcome variable was whether the patient underwent testing. Independent variables expected to predict testing were age, gender, race, Medicaid status, clinical characteristics, and hospital referral region (HRR).

Results: From 2010 to 2013, the number of test orders increased by 23.0%. Of the 256,818 patients identified in 2011-2012 claims, 25,352 (9.9%) underwent the 21-gene RS test. Estrogen receptor-positive status was the strongest positive predictor of testing (odds ratio (OR) 2.58, 95% confidence interval (CI) 2.48-2.69). White patients were more likely to be tested than minorities (OR 1.46, 95% CI 1.39-1.52). Secondary cancer was the strongest negative predictor. Medicaid recipients were less likely to be tested (OR 0.74, 95% CI 0.71-0.78). The likelihood of testing decreased with increasing age and comorbidities.

Conclusions: Despite widespread implementation of the 21-gene RS test, minorities and Medicaid recipients had less access to testing. Many patients with serious comorbidities or advanced age were tested even though the risk algorithm may not have been applicable to them.Genet Med advance online publication 23 March 2017.

Preoperative delays in the US Medicare population with breast cancer.
Richard J Bleicher, Karen Ruth, +6 authors, Brian L Egleston.
J Clin Oncol, 2012 Nov 22; 30(36). PMID: 23169513    Free PMC article.
Utilization of Oncotype DX in an Inner City Population: Race or Place?
Amber A Guth, Susan Fineberg, +2 authors, Nina A Bickell.
Int J Breast Cancer, 2014 Jan 24; 2013. PMID: 24455283    Free PMC article.
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Foluso O Ademuyiwa, Austin Miller, +5 authors, Sunil Badve.
Breast Cancer Res Treat, 2011 Jan 05; 126(3). PMID: 21197567
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
Molly E Klein, David J Dabbs, +4 authors, Rohit Bhargava.
Mod Pathol, 2013 Mar 19; 26(5). PMID: 23503643    Free PMC article.
Older women with localized breast cancer: costs and survival rates increased across two time periods.
Aaron J Feinstein, Jessica Long, +8 authors, Cary P Gross.
Health Aff (Millwood), 2015 Apr 08; 34(4). PMID: 25847641
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +3 authors, Lesley H Curtis.
JAMA Oncol, 2015 Jul 17; 1(2). PMID: 26181015
Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
Christos Markopoulos.
Expert Rev Anticancer Ther, 2013 Feb 15; 13(2). PMID: 23406559
Histopathologic variables predict Oncotype DX recurrence score.
Melina B Flanagan, David J Dabbs, +2 authors, Rohit Bhargava.
Mod Pathol, 2008 Mar 25; 21(10). PMID: 18360352
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Cancer statistics, 2010.
Ahmedin Jemal, Rebecca Siegel, Jiaquan Xu, Elizabeth Ward.
CA Cancer J Clin, 2010 Jul 09; 60(5). PMID: 20610543
Highly Cited.
Cancer management in patients with end-stage renal disease.
Jonathan D Eneman, George K Philips.
Oncology (Williston Park), 2005 Nov 01; 19(9). PMID: 16255135
Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
Julianne R Biroschak, Gordon F Schwartz, +4 authors, Sun Yong Lee.
Breast J, 2013 Apr 26; 19(3). PMID: 23614365
Who gets genomic testing for breast cancer recurrence risk?
J T DeFrank, T Salz, K Reeder-Hayes, N T Brewer.
Public Health Genomics, 2013 Aug 01; 16(5). PMID: 23899493    Free PMC article.
Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric.
Pharmacoeconomics, 2013 Nov 30; 32(2). PMID: 24288208
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +2 authors, Lesley H Curtis.
JAMA Oncol, 2015 Aug 28; 1(8). PMID: 26313372
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
Ann B Nattinger, Purushottam W Laud, +2 authors, Jean L Freeman.
Health Serv Res, 2004 Nov 10; 39(6 Pt 1). PMID: 15533184    Free PMC article.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.
Shelby D Reed, Michaela A Dinan, Kevin A Schulman, Gary H Lyman.
Genet Med, 2012 Sep 15; 15(3). PMID: 22975761    Free PMC article.
Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research.
Julie A Lynch, Muin J Khoury, +5 authors, Christopher S Lathan.
Genet Med, 2013 Mar 02; 15(8). PMID: 23448725    Free PMC article.
Survival trends in ESRD patients compared with the general population in the United States.
Carl van Walraven, Douglas G Manuel, Greg Knoll.
Am J Kidney Dis, 2013 Nov 12; 63(3). PMID: 24210591
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Nadia Howlader, Sean F Altekruse, +4 authors, Kathleen A Cronin.
J Natl Cancer Inst, 2014 Apr 30; 106(5). PMID: 24777111    Free PMC article.
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Oncotype testing in patients undergoing intraoperative radiation for breast cancer.
Kelsey E Larson, Stephanie A Valente, +7 authors, Stephen R Grobmyer.
Mol Clin Oncol, 2018 Oct 23; 9(5). PMID: 30345048    Free PMC article.
Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
Ronnie Zipkin, Andrew Schaefer, +3 authors, Erika L Moen.
Cancer Med, 2021 Jan 18; 10(4). PMID: 33455068    Free PMC article.
Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
Nicholas Acuna, Jesse J Plascak, +2 authors, Adana A M Llanos.
Int J Environ Res Public Health, 2021 Jun 03; 18(10). PMID: 34065945    Free PMC article.